secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001213900-23-088065
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax CEO Anthony Mack resigns due to ongoing litigation; Gerald Bruce named CEO, Eric Floyd Chairman
--------------------------------------------------------------------------------

- Anthony P. Mack resigned as CEO and Chairman effective November 17, 2023; resignation due to ongoing litigation.
- Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman, effective November 20, 2023.
- Gerald Bruce had served as EVP of Commercial Operations since 2017 and as President/CEO of subsidiary Novvae Pharmaceuticals.
- Dr. Eric Floyd, a board member since 2017, has over 25 years of pharmaceutical regulatory experience.
- Compensation for new CEO and Chairman has not yet been determined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/0001213900-23-088065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/ea188635-8k_virpaxpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-088065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer